Biosimilars benefit everyone. Biosimilars are FDA-approved alternatives to reference biologics – much like generic drugs – that provide treatment options for patients who need biologic medicines to manage their conditions.
Experts project that biosimilars could give 1.2 million patients access to treatments for rheumatoid arthritis, Crohn’s disease, cancer and other chronic conditions. In total, biosimilars have the potential to save the entire U.S. health care system $54 billion over the next ten years.
The infographic below shows how everyone — doctors, payers and patients — can benefit from biosimilars.